Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded the disease term Small cell lung carcinoma and the Genetic and Rare Diseases Information Center as a resources entry.SummaryDifference0.1%

- Check15 days agoChange DetectedStudy protocol revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange Detected- Revision: v3.4.3 has been added and Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page; this is a minor version change with no impact on core content — To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1; no changes to page content or layout are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check66 days agoChange DetectedUI and metadata updates are present, including a 'Show glossary' option, capitalization adjustments for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and a revision indicator updated to v3.4.0. These changes do not alter core study content, endpoints, or results display.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.